Skip to main content
. 2023 Nov 5;24(21):15984. doi: 10.3390/ijms242115984

Table 1.

The exome-wide association study analysis of IgAN patients and control groups.

GENE CHR POSITION MARKER BONF A1 F_A F_U A2 CHISQ p OR (95% CI) SE
Additive
PRAG1 8 8,176,387 rs143409664 1.808 × 10–15 CGGGGCG 0.4571 0.07692 C 179.8 5.464 × 10–41 10.11 (6.834–14.94) 0.1996
ZNF787 19 56,599,437 rs5828672 2.926 × 10–14 C 0.4929 0.07849 CTCG 205.8 1.13 × 10–46 11.41 (7.731–16.84) 0.1986
TRBV5-4 7 142,168,890 rs767448033 3.146 × 10–12 T 0.3571 0.07849 C 103.3 2.906 × 10–24 6.522 (4.365–9.745) 0.2048
TENM3 4 183,370,244 rs35591339 5.646 × 10–12 A 0.5071 0.08399 AGCG 205.3 1.485 × 10–46 11.22 (7.629–16.51) 0.1969
PIM1 6 37,138,023 rs1300416314 2.207 × 10–11 G 0.4286 0.1148 GGCA 99.66 1.81 × 10–23 5.784 (3.969–8.429) 0.1921
CYTH2 19 48,985,178 rs34527214 7.812 × 10–10 TA 0.5357 0.1546 T 117.9 1.814 × 10–27 6.308 (4.378–9.089) 0.1863
MISP3 19 14,184,713 rs35666756 8.00 × 10–9 CG 0.3429 0.09105 C 78.01 1.028 × 10–18 5.208 (3.499–7.753) 0.2029
EOMES 3 27,763,427 rs368178421 3.243 × 10–8 GCGGCGC 0.3623 0.1009 G 76.89 1.805 × 10–18 5.06 (3.418–7.491) 0.2001
FBXO27 19 39,505,111 rs4803184 3.255 × 10–8 G 0.4786 0.1389 A 101.9 5.818 × 10–24 5.688 (3.938–8.216) 0.1876
SH3PXD2A 10 105,428,453 rs10533306 3.656 × 10–8 C 0.4714 0.1852 CAG 61.51 4.41 × 10–15 3.923 (2.735–5.627) 0.184
Dominant
PRAG1 8 8,176,387 rs143409664 1.654 × 10–15 CGGGGCG 0.4571 0.07692 C 179.8 5.464 × 10–41 10.11 (6.834–14.94) 0.1996
TRBV5-4 7 142,168,890 rs767448033 3.146 × 10–12 T 0.3571 0.07849 C 103.3 2.906 × 10–24 6.522 (4.365–9.745) 0.2048
ZNF787 19 56,599,437 rs5828672 3.25 × 10–11 C 0.4929 0.07849 CTCG 205.8 1.13 × 10–46 11.41 (7.731–16.84) 0.1986
PIM1 6 37,138,023 rs1300416314 1.187 × 10–10 G 0.4286 0.1148 GGCA 99.66 1.81 × 10–23 5.784 (3.969–8.429) 0.1921
MISP3 19 14,184,713 rs35666756 3.523 × 10–9 CG 0.3429 0.09105 C 78.01 1.028 × 10–18 5.208 (3.499–7.753) 0.2029
EOMES 3 27,763,427 rs368178421 3.964 × 10–9 GCGGCGC 0.3623 0.1009 G 76.89 1.805 × 10–18 5.06 (3.418–7.491) 0.2001
SREBF1 17 17,740,164 rs60282872 2.629 × 10–8 G 0.2643 0.08477 GC 44.17 3.013 × 10–11 3.878 (2.537–5.928) 0.2165
PRTN3 19 843,692 rs2301879 3.49 × 10–8 G 0.2929 0.08948 A 53.45 2.646 × 10–13 4.214 (2.792–6.361) 0.2101
AMACR 5 34,008,206 rs3217251 6.688 × 10–8 C 0.2857 0.08085 CCGGCGCCACGCCCCCAGCCG 58.24 2.322 × 10–14 4.548 (2.993–6.91) 0.2135
CHRNA3 15 78,913,067 rs751352647 1.363 × 10–7 A 0.4214 0.1546 ACAG 60.56 7.149 × 10–15 3.982 (2.755–5.755) 0.1879
Recessive
UBR3 2 170,871,976 rs13028230 1.545 × 10–9 A 0.5429 0.2951 G 35.59 2.431 × 10–9 2.836 (1.991–4.039) 0.1804
PKD1L1 7 47,835,116 rs2348459 2.031 × 10–9 T 0.5571 0.2363 C 66.2 4.077 × 10–16 4.067 (2.844–5.815) 0.1825
DNAH11 7 21,639,818 rs6461586 2.649 × 10–9 T 0.3643 0.1586 C 36.34 1.657 × 10–9 3.041 (2.089–4.427) 0.1916
CIAO2A 15 64,381,148 rs16947748 2.861 × 10–9 G 0.5786 0.2841 A 50.83 1.01 × 10–12 3.459 (2.421–4.942) 0.1821
TRMT9B 8 12,870,438 rs2466264 6.754 × 10–9 C 0.6714 0.3265 G 65.07 7.224 × 10–16 4.215 (2.907–6.112) 0.1896
MDN1 6 90,400,292 rs954638 9.888 × 10–9 C 0.4929 0.179 T 74.9 4.943 × 10–18 4.458 (3.108–6.397) 0.1842
PIEZO2 18 10,757,868 rs7242408 1.003 × 10–8 A 0.5071 0.2276 G 51.83 6.039 × 10–13 3.491 (2.445–4.986) 0.1818
OR10G6 11 123,865,086 rs7944434 1.053 × 10–8 A 0.4571 0.1743 C 62.56 2.583 × 10–15 3.991 (2.777–5.735) 0.185
PWP2 21 45,547,563 rs2242954 1.658 × 10–8 G 0.4 0.1931 C 32.15 1.427 × 10–8 2.786 (1.933–4.016) 0.1865
BAIAP2 17 79,084,072 rs4072588 2.268 × 10–8 T 0.5214 0.2339 G 53.88 2.132 × 10–13 3.568 (2.499–5.095) 0.1817

Notes: CHR—chromosome, POSITION—base pair based on the human reference genome GRCh37, A1—minor allele, F_A—frequency of A1 allele in patients, F_U—frequency of A1 allele in controls, A2—major allele, CHISQ—basic allelic test chi-square (1df), pp-value for CHISQ, OR (95% CI)—odds ratio and confidence interval for odds ratio, SE—standard error, BONF—Bonferroni single-step adjusted p-values.